Study S000116

Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02847403
Acronym: DRINN
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: UNKNOWN
Enrollment: 40
Start: 2016-02
Primary completion: 2019-07
Lead sponsor: Azienda Ospedaliero-Universitaria di Parma
Conditions: Dysglycemia; Cognitive Deficit
Interventions: DRUG:Exenatide; OTHER:placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: NIH:2015

Registered primary outcomes

Improvement of ADAS-cog Alzheimer's Disease Assessment Scale defined by ADAS-cog score at 16 (V2) and at 32 weeks (V3) compared to baseline [16 and 32 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024470	Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. McClean PL, Neuropharmacology	2014	Preclinical	PMID 23973293 DOI	registry reference BACKGROUND:23973293
R0026610	Exenatide and the treatment of patients with Parkinson's disease. Aviles-Olmos I, The Journal of clinical investigation	2013	Randomized trial	PMID 23728174 DOI	registry reference BACKGROUND:23728174
R0027004	Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Perry T, Experimental neurology	2007	Preclinical	PMID 17125767 DOI	registry reference BACKGROUND:17125767